Blood pressure control in patients with comorbidities

Journal of Clinical Hypertension

Volumn 10, Issue 8, 2008, Pages 624-631

  Schmieder, Roland E ^a   Ruilope, Luis M ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LISINOPRIL; LOSARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG CHOICE; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LABORATORY DIAGNOSIS; LIPOLYSIS; METABOLIC SYNDROME X; MICROALBUMINURIA; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SIDE EFFECT; TREATMENT PLANNING; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; DRUG COMBINATION; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 52649140632     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.08172.x     Document Type: Review

References (56)

1. Weycker D, Nichols GA, O'Keefe-Rosetti M, et al. Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens. 2007;20:599-607.
2. Alberti KG, Zimmett P, Shaw J. The metabolic syndrome: A new worldwide definition. Lancet. 2005;366:1059-1062.
3. Wahrenberg H, Hertel K, Leijonhufvud BM, et al. Use of waist circumference to predict insulin resistance: Retrospective study. BMJ. 2005;330:1363-1364.
4. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Final Report. Circulation. 2002;106:3143-3421.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
6. Grundy SM. Metabolic syndrome: A multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007;92:399-404.
7. Mulè G, Nardi E, Cottone S, et al. Relationship of metabolic syndrome with pulse pressure in patients with essential hypertension. Am J Hypertens. 2007;20:197-203.
8. Rodondi N, Peng T, Karter AJ, et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med. 2006;144:475-484.
9. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462-1536.
10. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549-1555.
11. Kotsis V, Stabouli S, Bouldin M, et al. Impact of obesity on 24-hour ambulatory blood pressure and hypertension. Hypertension. 2005;45:602-607.
12. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41:625-633.
13. Schmieder RE, Messerli FH. Does obesity influence early target organ damage in hypertensive patients? Circulation. 1993;87:1482-1488.
14. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
15. Goodfriend TL, Calhoun DA. Resistant hypertension obesity, sleep apnea and aldosterone: Theory and therapy. Hypertension. 2004;43:518-524.
16. Banegas JR, Segura J, Ruilope L, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension. 2004;43:1338-1344.
17. Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
18. Calle EE, Thun M, Petrelli J, et al. Body-mass index and mortality in a prospective cohort. N Engl J Med. 1999;341:1097-1105.
19. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-313.
20. Gates PE, Gentile CL, Seals DR, et al. Adiposity contributes to differences in left ventricular structure and diastolic function with age in healthy men. J Clin Endocrinol Metab. 2003;88:4884-4890.
21. Sharma AM, Engeli S. Managing big issues on lean evidence: Treating obesity hypertension. Nephrol Dial Transplant. 2002;17:353-355.
22. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension and cardiovascular disease: An update. Hypertension. 2001;37:1053-1059.
23. Berlowitz DR, Ash A, Hickey E, et al. Hypertension management in patients with diabetes: The need for more aggressive therapy. Diabetes Care. 2003;26:355-359.
24. Zgibor JC, Wilson RR, Orchard TJ, et al. Has control of hypercholesterolemia and hypertension in type 1 diabetes improved over time? Diabetes Care. 2005;28:521-526.
25. McFarlane SI, Jacober S, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care. 2002;25:718-723.
26. Schaars CF, Denig P, Kasje WN, et al. Physician, organizational, and patient factors associated with suboptimal blood pressure management in type 2 diabetic patients in primary care. Diabetes Care. 2004;27:123-127.
27. Dahlöf B, Sever P, Poulter N, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicenter randomized controlled trial. Lancet. 2005;366:895-906.
28. Maahs DM, Kinney G, Wadwa P, et al. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005;28:301-306.
29. Andersen NH, Poulsen P, Knudsen S, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes. The CALM II study. Diabetes Care. 2005;28:273-277.
30. Bakris GL, Gaxiola E, Messerli F, et al. Clinical outcomes in the diabetes cohort of the international verapamil SR-trandolapril study. Hypertension. 2004;44:637-642.
31. Nelson RG, Knowler WC, Pettit DJ, et al. Kidney diseases in diabetes. In: Diabetes in America, National Institutes of Health Publication No. 95-1468. 2nd ed. 2. Bethesda, MD: National Institutes of Health; 1995:349-400.
32. Zanchetti A, Hansson L, Dahlöf B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients in the Hypertension Optimal Treatment study. J Hypertens. 2001;19:1149-1159.
33. Nakano S, Fukuda M, Hotta F, et al. Reversed circadian blood pressure rhythm is associated with occurrence of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes. 1998;47:1501-1506.
34. Fogari R, Zoppi A, Malamani GD, et al. Ambulatory blood pressure monitoring in normotensive and hypertensive type 2 diabetes. Prevalence of impaired diurnal blood pressure patterns. Am J Hypertens. 1993;6:1-7.
35. Kuch B, von Scheidt W, Peter W, et al. Influence of antihypertensive therapy and blood pressure control in left ventricular geometry and function in subjects with type II diabetes: The Augsburg Diabetes Family Study. J Hum Hypertens. 2006;20:757-764.
36. UK Prospective Diabetes Study group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
37. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
38. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
39. McInnes GT. How important is optimal blood pressure control? Clin Ther. 2004;26(suppl A):A3-A11.
40. Patel A; ADVANCE Collaborative Group. Effects of a fixed combination of preindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomized controlled trial. Lancet. 2007;370:829-840.
41. Parving HH, Lewis JB, Lewis EJ, et al. Aliskiren in the evaluation of proteinuria in diabetes (AVOID). N Engl J Med. 2008;358:2433-2446.
42. Cowie MR. Simultaneous treatment of hypertension and dyslipidemia may help to reduce overall cardiovascular risk: Focus on amlodipine/ atorvastatin single-pill therapy. Int J Clin Pract. 2005;59:839-846.
43. Laffer CL, Elijovich F. Suboptimal outcome of management of metabolic cardiovascular risk factors in Hispanic patients with essential hypertension. Hypertension. 1995;26:1079-1084.
44. Battleman DS, Peterson ED. Estimated prevalence of comorbid hypertension and dyslipidemia and therapeutic goal attainment among US adults in 2000, utilizing data from the National Health and Nutrition Examination Survey (NHANES II). J Manag Care Pharm. 2004;10:186.
45. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147-1152.
46. Thomas F, Bean K, Guize L, et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J. 2002;23:528-535.
47. Emberson J, Whincup P, Morris R, et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004;25:484-491.
48. Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100:1254-1262.
49. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
50. Julius S, Kjeldsen SE, Weber MA, et al.; VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine; the VALUE randomized trial. Lancet. 2004;363:2049-2051.
51. Moser M. New-onset diabetes in the hypertension treatment trials: A point of view. J Clin Hypertens (Greenwich). 2004;6:610-613.
52. Aksnes TA, Schmieder RE, Kjeldsen SE, et al. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol. 2008;101(5):634-638.
53. Hennes MMI, O'Shaughnessy IM, Kelly TM, et al. Insulin-resistant lipolysis in abdominally obese hypertensive individuals: Role of the renin-angiotensin system. Hypertension. 1996;28:120-126.
54. CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542-2551.
55. Gilmer TP, O'Connor P, Rush W, et al. Predictors of health care costs in adults with diabetes. Diabetes Care. 2005;28:59-64.
56. Sesso HD, Chen RS, L'Italien GJ, et al. Blood pressure lowering and life expectancy based on a Markov model of cardiovascular events. Hypertension. 2003;42:885-890.